Results 151 to 160 of about 4,502 (202)
[Aprepitant and pruritus--comment].
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013 openaire +1 more source
Hospital Pharmacy, 2003 Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Aprepitant – a novel NK1-receptor antagonist
Expert Opinion on Pharmacotherapy, 2003Recently, a new class of agents, the substance P antagonists, has heralded a novel approach for the control of emesis. Aprepitant (Emend, Merck & Co., Inc.), the first of this class, was recently approved by the FDA for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Lisa Patel
exaly +3 more sources
, 2016 This is a poster presented at the Natural Sciences Poster Session at Parkland College, which provides the chemical makeup, dosage, and the body\u27s response to Aprepitant, also known as Emend, a medication used to prevent acute and delayed nausea and ...
Pagan, Genesis N, Mark G. Papich
core +6 more sources
British Journal of Anaesthesia, 2007 Background. the neurokinin(l) antagonist aprepitant is effective for prevention of chemotherapy-induced nausea and vomiting. We compared aprepitant with ondansetron for prevention of postoperative nausea and vomiting.Methods.
P Diemunsch, T J Gan, L Eberhart
exaly +3 more sources
Comparisons of aprepitant and ondansetron
American Journal of Health-System Pharmacy, 2007We are responding to the letter from Cavaretta and Noviasky[1][1] concerning Merck’s two Phase III studies of aprepitant 40 mg p.o. versus ondansetron 4 mg (as the hydrochloride salt) i.v. in the prevention of postoperative nausea and vomiting (PONV).[2][2],[3][3] Prophylactic ondansetron ...
Alexandra, Carides +4 more
openaire +2 more sources
Aprepitant for Erlotinib-Induced Pruritus
New England Journal of Medicine, 2010To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic ...
Vincenzi B, Tonini G, Santini D
openaire +3 more sources
Journal Of Pain & Palliative Care Pharmacotherapy, 2005
Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults.
openaire +3 more sources
Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults.
openaire +3 more sources